October 10, 2020

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

staff reporter

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics.

Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed.

Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation sequencing analysis technology into its own platform. The Geneyx system provides artificial intelligence-based processing, with help from LifeMap Sciences’ GeneCards knowledgebase.

As part of the acquisition, former Toldot CEO Dvir Dahary has become chief scientist of Geneyx. “Geneyx’s technology provides biomedical interpretation capabilities for more than 18 percent of the genome … which enables researchers to better leverage the power of whole-genome sequencing data for better clinical diagnosis and for distilling novel findings that will lead to the development of the next generation of targeted and personalized therapeutics,” Dahary said in a statement.

“Too much of the genetic data generated today is sitting in ‘silos’ in hospitals around the world, and this data can be better used by researchers for drug discovery and novel therapeutics, ” added Geneyx Chief Marketing Officer Raviv Ithaki. “By offering hospitals with better diagnostic solutions, and pharma with a targeted and sophisticated research platform, we will offer better care for patients with precise and preventive medicine.”

Geneyx and BATM are part of a public-private consortium in Israel that is collecting samples and sequencing genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the hopes of discovering new diagnostic and treatment methods for the novel disease.

Additional Articles

News

PacBio Geneyx Press Release

November 1, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partner Geneyx to PacBio Compatible

PacBio

Partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

Geneyx

Geneyx and Ocean Genomics develop a multiomic software method, combining DNA and RNA.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

BIRD Foundation invests $8 million in 9 new projects

James Spiro

Geneyx and Ocean Genomics will develop a multiomic software method, combining DNA and RNA.

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

June 21, 2023

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

Neil Versel

This month's announcement that Oxford Nanopore Technologies would integrate its Epi2Me cloud-based analysis platform with Geneyx's software to automate analysis and clinical reporting of long-read sequencing data

Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing

June 9, 2023

Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing

Business Wire

The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced, "one-click" solution.

Oxford Nanopore Technologies and Geneyx collaboration

June 9, 2023

Oxford Nanopore Technologies and Geneyx announce the first scalable software solution to advance the future clinical use of nanopore sequencing

Oxford Nanopore Technologies

England--Oxford Nanopore Technologies. The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced,

Previous
Next
PacBio Geneyx Press Release

November 1, 2023

PacBio Enables Rare and Inherited Disease Research by Adding Tertiary Analysis Partner Geneyx to PacBio Compatible

PacBio

Partnerships maximize value of HiFi data and complete the full end-to-end workflow for PacBio customers.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

Geneyx

Geneyx and Ocean Genomics develop a multiomic software method, combining DNA and RNA.

Geneyx and Ocean Genomics Collaborate to Enhance Genomic Variant Detection for Improved Disease Diagnosis and Drug Target Identification

July 26, 2023

BIRD Foundation invests $8 million in 9 new projects

James Spiro

Geneyx and Ocean Genomics will develop a multiomic software method, combining DNA and RNA.

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

June 21, 2023

Bioinformatics Startup Geneyx Builds Business on Whole-Genome, Long-Read Sequencing Analysis

Neil Versel

This month's announcement that Oxford Nanopore Technologies would integrate its Epi2Me cloud-based analysis platform with Geneyx's software to automate analysis and clinical reporting of long-read sequencing data

Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing

June 9, 2023

Oxford Nanopore Technologies and Geneyx Announce the First Scalable Software Solution to Advance the Future Clinical Use of Nanopore Sequencing

Business Wire

The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced, "one-click" solution.

Oxford Nanopore Technologies and Geneyx collaboration

June 9, 2023

Oxford Nanopore Technologies and Geneyx announce the first scalable software solution to advance the future clinical use of nanopore sequencing

Oxford Nanopore Technologies

England--Oxford Nanopore Technologies. The new platform is designed to enable the end-to-end analysis and clinical reporting of nanopore sequencing, empowering clinical labs, researchers and other users with an advanced,

+

Selected Videos

Geneyx Analysis Version 5.12 Release

Previous
Next